CTIS2024-514441-11-00招募中1 期
To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. - BUTTERFLY
Instytut Matki I Dziecka0 个研究点目标入组 24 人开始时间: 2024年7月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Histologically proven Ewing sarcoma of the bone or soft tissues., Consent to the use of effective contraception throughout the period of the study and a minimum of 1 year after discontinuation of study treatment in patients at puberty and sexual maturity., Subject's archival tumour sample (formalin-fixed, paraffinembedded; FFPE) available for evaluation of GD2 expression., Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence., GD2 positive tumor assessed by IHC., Age = 2 years and = 21 years., Life expectancy of at least 12 weeks from the time informed consent was signed., Previous systemic anticancer treatment completed = 3 weeks, major surgery = 2 weeks, and radiation therapy = 4 weeks prior to study enrollment., Recovered from adverse effects of prior surgery, radiotherapy, or anti-neoplastic therapy at the discretion of the investigator., Signing of informed consent for trial participation (including for naxitamab treatment) according with current legal regulations.
排除标准
- •Failure to meet any of the inclusion criteria., Requirement, or likely requirement, for corticosteroids at doses >10 mg prednisolone (or equivalent) per day or other immunosuppressive agents., Diagnosis of other malignancies before study inclusion., Planning to become pregnant (while being treated with IT or naxitamab), pregnancy or breastfeeding., Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial., Not eligible to IT., Previous treatment with an anti-GD2 antibody., Hypersensitivity to the study drugs or any of their ingredients (covers IT and naxitamab)., Simultaneous treatment with other drugs which might interact with naxitamab or IT regimen., Persistent toxicity related to prior therapy, making it impossible to treat with naxitamab., Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening QTc >480 msec., Symptoms of congestive heart failure or left ventricular ejection fraction <50%., Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry < 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated.
研究者
相似试验
招募中
2 期
To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.Ewing's sarcoma2024-514441-11-00Instytut Matki I Dziecka24
招募中
2 期
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)Ewing SarcomaNCT05968768Anna Raciborska24
已完成
2 期
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory NeuroblastomaRefractory NeuroblastomaSoft Tissue CancerNCT06438614Fundació Sant Joan de Déu47
招募中
Unknown
TRodelvy use in AdvanCed TrIple Negative BrEast Cancer in Australia (TRACIE)ACTRN12623000931673Walter and Eliza Hall Institute200
招募中
2 期
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaNeuroblastomaNCT06013618Sun Yat-sen University120